Biomarin Pharmaceutical (BMRN) Invested Capital (2009 - 2026)

Biomarin Pharmaceutical has disclosed Invested Capital across 18 years of filings, most recently posting $7.6 billion for Q1 2026.

• Quarterly Invested Capital rose 31.91% year-over-year to $7.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.6 billion (up 31.91% YoY) and the FY2025 annual result came in at $6.7 billion, up 18.14% from the prior year.
• Invested Capital climbed to $7.6 billion in Q1 2026, from $6.7 billion in the prior quarter.
• Over five years, Invested Capital peaked at $7.6 billion in Q1 2026 and troughed at $4.5 billion in Q1 2022.
• A 5-year average of $5.4 billion and a median of $5.4 billion in 2023 frame the typical range for Invested Capital.
• Annual changes were most pronounced in 2024 — Invested Capital grew 3.9% — and 2026, when it soared 31.91%.
• Tracing BMRN's Invested Capital over 5 years: stood at $4.6 billion in 2022, then rose by 18.3% to $5.4 billion in 2023, then grew by 3.9% to $5.7 billion in 2024, then grew by 18.14% to $6.7 billion in 2025, then climbed by 14.34% to $7.6 billion in 2026.
• Business Quant data shows BMRN's Invested Capital at $7.6 billion in Q1 2026, $6.7 billion in Q4 2025, and $6.1 billion in Q3 2025.